It’s often a women’s problem that embarrassment keeps in the dark, but an O’Hara company is getting closer to marketing a treatment.
Early studies have been promising for the growing biotech company, which is planning to begin marketing its first cell therapy for urinary incontinence in 2019, pending regulatory approval. Up to 70 percent of people treated for the condition reported symptom improvement after receiving adult muscle cells processed by Cook MyoSite Inc.
The company continues to enroll people in a phase three Food and Drug Administration trial for the treatment. Enrollment is expected to last through the end of the year, according to Ryan Pruchnic, vice president of operations, who was Cook Myosite’s first employee.
“We’re testing the product against a placebo now,” said Mr. Pruchnic, 41, a Somerset County native.
Urinary incontinence affects millions of people, especially women after childbirth or menopause because of muscle weakness in the lower urinary tract. Coughing, laughing, sneezing or jogging can cause sudden urinary release, the most common bladder control problem in women.
Cook Group, a medical device company based in Bloomington, Ind., licensed the cell therapy technology in 2002 from the University of Pittsburgh, which Mr. Pruchnic and Pleasant Hills native Ron Jankowski, 44, who is vice president of product development, helped develop as graduate students. Cook MyoSite operates as a subsidiary of Cook Group.
Cook MyoSite is pursuing FDA approval for its first cell therapy product, but the company also manufactures and sells supplies that are used in academic and corporate labs.
The company processes the patient’s own skeletal muscle cells, then instructs doctors in the injection of the treated cells near the bladder. The technique is intended to strengthen the muscles.
Based on early success of the technology, Cook MyoSite is expanding its manufacturing capabilities in RIDC park from about 5,000 to 66,000 square feet. The company is refurbishing a building next to its corporate offices, which will be redone to accommodate aseptic manufacturing practices and to create a global distribution center. Occupancy of the new buidling is expected by November.
The company plans to invest at least $26 million into the project while continuing to explore use of its cell therapy platform for treatment of fecal incontinence and to restore tongue muscles weakened by radiation therapy.
Cook Myosite anticipates adding 50 employees by year’s end, bringing its total workforce to 98.
Kris B. Mamula: kmamula@post-gazette.com





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.